31 articles
With seven UK patients implanted under the GB-PRIME study and a total of twenty worldwide, Neuralink's R1 surgical robot has moved to Cleveland Clinic Abu Dhabi for the next cohort under the UAE-PRIME trial.
The German neurotech company becomes the first to receive FDA Breakthrough Device Designation for a brain-computer interface targeting motor recovery after stroke, with its closed-loop Brain Interchange system showing meaningful recovery in a Harborview Medical Center trial.
Neurosurgeon Daniel Kramer implants a BCI in a quadriplegic patient at UCHealth University of Colorado Hospital, with electrodes placed in higher-level brain areas rather than motor cortex alone.
Galen Buckwalter, a quadriplegic research psychologist with six Utah arrays in his brain, is using a Caltech-developed interface to generate music directly from neural signals.
The startup, led by iota Biosciences founder Michel Maharbiz, is developing a minimally invasive brain-computer interface that pairs neural decoding with a motorized grip-assist glove to restore movement after stroke.
The Austin-based company is now enrolling participants at the University of Michigan and Massachusetts General Hospital for the Connect-One study, the first clinical trial of a fully implantable BCI designed to restore speech.
The FOCUS-AU trial will test Synchron's advanced brain-computer interface in ten MND patients across three Australian hospitals, with surgery beginning in April.
Five patients now carry the coin-sized wireless implant that sits on the brain's protective membrane rather than penetrating tissue, with one ALS patient decoding nearly 100 Chinese words.
The Pennsylvania company's 60-channel Smart Neurostimulation System is the first device to receive Breakthrough Device Designation for TBI-related memory loss.
The Swedish company's FL-100 headset, cleared via the FDA's most stringent PMA pathway, launches in the US in Q2 2026 after a 174-person Nature Medicine trial. A second device, Neurolief's ProlivRx, was approved weeks later.
NeuCyber Neurotech's rotating CEO concedes a significant technology gap with Musk's outfit, even as China pours state funding into catching up and expanding human trials to 50 patients.
The Austin-based neurotech company launches its APEX Partnership Program with five leading research institutions, aiming to push its Connexus brain-computer interface beyond speech restoration into stroke recovery, Parkinson's and motor rehabilitation.
The Leuven-based neurotech company's Occular system, which uses thousands of micro-electrodes implanted in the visual cortex to restore functional sight, has received FDA Breakthrough Device Designation.
Neuracle Medical Technology secures NMPA clearance, making its coin-sized cortical implant the first invasive BCI anywhere in the world authorised for routine clinical sale.
The Mark Cuban-backed startup releases a behind-the-scenes demo of Atlas, a non-invasive brain-computer interface that translates scalp-measured neural activity into real-time wheelchair navigation using deep learning and large-scale neural datasets.
The $20 billion data centre operator partners with the Melbourne startup that taught neurons to play Doom, planning to deploy up to 1,000 biological compute units powered by living human brain cells.
Multiple companies, including Elon Musk's Neuralink, are racing to bring brain-computer interface technology out of research labs and into commercial markets.
Michael, a quadriplegic patient, uses 256 microelectrodes implanted in his brain to regain autonomy through thought-controlled computing. Researchers in Munich demonstrate how BCIs are moving from experimental to practical.
AlterEgo, spun out from MIT Media Lab, showcases wearable device that translates internal speech into digital commands without vocalization.
The Chinese neural interface company begins construction of the country's first dedicated manufacturing facility for implantable brain-computer interfaces in Nanchang, signaling a shift from lab to production line.
With 12+ patients implanted and mass production planned for 2026, Neuralink's clinical reality is more complicated and more human than the headlines suggest.
The stablecoin giant invests in AI-powered sleep technology company Eight Sleep, extending a biotech investment strategy that began with its $200 million majority stake in Blackrock Neurotech.
Kim Han-sol, a blind YouTuber with 1.68 million subscribers, has publicly applied for Neuralink's Blindsight clinical trial, bringing significant public attention to the experimental vision-restoring brain implant.
A new partnership between Science Corp and Neurosoft AI aims to dramatically reduce the cost and timeline of brain-computer interface clinical trials through shared infrastructure and software tools.
AIIMS Delhi performs first auditory brainstem implant in India, demonstrating neural bypass technology's potential for patients unsuitable for conventional cochlear devices.
A Chinese company is developing non-invasive ultrasound brain-computer interfaces to treat chronic pain, intensifying competition in alternatives to surgical neural implants.
A major clinical trial shows wireless neural implants restored meaningful central vision to those blinded by macular degeneration, with participants reading letters and words.
Cortical Labs demonstrated human brain cells on a chip mastering basic gameplay within seven days, advancing the case for biological computing in real-world applications.
Chinese BCI company NeuroXess has surpassed human trial milestones, positioning itself as a direct competitor to Neuralink in the global neural interface market.
Brazilian neuroscientist Miguel Nicolelis leads research with Chinese collaborators demonstrating that brain-computer interface technology can trigger neural reorganization and restore movement in paralyzed patients.
FDA grants approval for Neuralink to enroll significantly more participants in its brain-computer interface clinical trials, marking a major step toward commercialization.
Get the latest BCI news, breakthroughs, and market moves delivered to your inbox.
No spam. One-click unsubscribe. We respect your privacy.